Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Octreotide + Sargramostim + SurVaxM |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Octreotide | Atrigel | Octreotida [Spanish] | ||
| Sargramostim | Leukine | GM-CSF|Prokine | ||
| SurVaxM | SVN53-67/M57-KLH | SurVaxM (SVN53-67/M57-KLH) is a peptide vaccine targeting survivin (Birc5), which may induce anti-tumor immune response (PMID: 27576783). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03879694 | Phase I | Octreotide + Sargramostim + SurVaxM | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | Completed | USA | 0 |